Paris, France and Camberley, UK – 1 October 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised
Visit PageCategory: Services
NOVACYT HALF YEAR 2018 RESULTS Molecular product revenues up 18% to €3m Gross margin increases to 64%
Novacyt half year 2018 results Paris, France and Camberley, UK – 26 September 2018 – Novacyt (ALTERNEXT: ALNOV; AIM: NCYT), an international specialist in clinical diagnostic products, today announces unaudited financial results for the six months ended 30 June 2018.
Visit PageNOVACYT PARTNERS WITH APPLIED MICROARRAYS IN ASSAY DESIGN
Novacyt partners with Applied Microarrays US partnership to facilitate the design and optimisation for customised microarray assays
Visit Page